🇺🇸 FDA
Company

Chemomab

Chemomab Therapeutics

CMMB pharma USA

Quick answer

Chemomab is a pharma company (CMMB) headquartered in TEL AVIV, USA with 6 tracked pipeline programs.

Pipeline (6)

project

10 mg/kg CM-101

Systemic Sclerosis

Phase 2 · small_molecule · on_hold

1 trials project

5 mg/kg CM-101

Nonalcoholic Steatohepatitis

Phase 2 · mab · completed

1 trials project

Anti-human CCL24 monoclonal antibody (CM-101)

Primary Sclerosing Cholangitis

Phase 2 · mab · active

1 trials project

Anti-human CCL24 monoclonal antibody (CM-101)

Healthy

Phase 1 · small_molecule · completed

1 trials project

Anti-human CCL24 monoclonal antibody (CM-101) - Part One

Nonalcoholic Fatty Liver Disease

Phase 1 · small_molecule · completed

1 trials project

CM-101

Nonalcoholic Steatohepatitis (NASH)

Phase 1 · small_molecule · completed

1 trials

Patents (4)

patent

US 12018074

Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases

Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11365246

Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases

Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10479830

Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10246508

Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)